StockNews.AI • 13 days
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
Original sourceXORTX Therapeutics has secured an extension until March 31, 2026, to finalize the acquisition of the VB4-P5 program, a promising therapy for kidney fibrosis. This extension highlights potential advancements in kidney disease treatment, which could positively impact investor sentiment and the company's market valuation.
Acquisition extends the timeline for a promising program, potentially alleviating investor concerns. Successful acquisition could validate business strategy and lead to positive sentiment.
Consider accumulating shares of TSXV:XRTX, targeting potential price appreciation in the short term as acquisition progresses.
This fits in the 'Corporate Developments' category as it pertains to M&A timelines and shareholder actions that can influence market perception and financial valuations for XORTX.